There is increasing evidence that monoclonal proteins are implicated in the development of peripheral neuropathy. Approximately ten percent of patients with peripheral neuropathy of unknown cause have a monoclonal protein and this rate is significantly higher than prevalence rates of monoclonal protein in comparable segments of the general population. Extensive clinical, electrophysiological and immunopathological evidences indicate that peripheral neuropathy associated with monoclonal protein are heterogeneous, including: 1. the demyelinating, predominantly sensory neuropathies associated with anti-MAG antibodies; 2. the axonal, sensory neuropathies associated with anti-sulfatide and anti-chondroitin sulfate antibodies; 3. the motor neuropathies associated with anti-GM1 antibodies. Patients with chronic polyneuropathies should be evaluated for underlying plasma cell dyscrasia.

Neuropathies associated with monoclonal gammapathies / R. Nemni, E. Gerosa, G. Piccolo, G. Merlini. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 79:6(1994), pp. 557-66-566.

Neuropathies associated with monoclonal gammapathies

R. Nemni
Primo
;
1994

Abstract

There is increasing evidence that monoclonal proteins are implicated in the development of peripheral neuropathy. Approximately ten percent of patients with peripheral neuropathy of unknown cause have a monoclonal protein and this rate is significantly higher than prevalence rates of monoclonal protein in comparable segments of the general population. Extensive clinical, electrophysiological and immunopathological evidences indicate that peripheral neuropathy associated with monoclonal protein are heterogeneous, including: 1. the demyelinating, predominantly sensory neuropathies associated with anti-MAG antibodies; 2. the axonal, sensory neuropathies associated with anti-sulfatide and anti-chondroitin sulfate antibodies; 3. the motor neuropathies associated with anti-GM1 antibodies. Patients with chronic polyneuropathies should be evaluated for underlying plasma cell dyscrasia.
Prednisone; Demyelinating Diseases; Combined Modality Therapy; Humans; Aged; Paraproteinemias; Immunosuppressive Agents; Nerve Tissue Proteins; Autoantigens; Paraproteins; Autoantibodies; Peripheral Nervous System Diseases; Adult; Carbohydrate Sequence; Molecular Sequence Data; Middle Aged; Plasmapheresis; Motor Neuron Disease; Female; Male
Settore MED/26 - Neurologia
Settore MED/04 - Patologia Generale
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/182868
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 26
  • ???jsp.display-item.citation.isi??? ND
social impact